Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer

Table 1 Clinicopathologic data obtained from 177 gastric cancer patients

	Patients
	n	%
Tumor size (cm) (mean ± SD)	6.0 ± 2.9
Location
Upper or whole body	40	22.6
Lower or middle body	137	77.4
Gross type
Localized	39	22.0
Infiltrative	138	78.0
Depth of invasion
T1	25	14.1
T2	86	48.6
T3	44	24.9
T4	22	12.4
Retrieved lymph nodes (mean ± SD)	22.4 ± 3.5
Stage
I	6	3.4
II	29	16.4
III	88	49.7
IV	54	30.5

Table 2 Preponderant histological type of primary and metastatic lymph nodes in 177 gastric cancer patients

Tumor type	Grade					P value
	-	+	++	+++	++++
Primary lymph nodes	0	0	7	69	101	< 0.01
Metastatic lymph nodes	17	8	14	44	94

Table 3 MMP-2 immunoreactivity in primary and metastatic T3 gastric cancer

Patients (n)	Tumor type	Grade				P value
		-	+	++	+++
44 T3NxMx	Primary lesion	12	6	14	12	0.004
Patients	Metastatic lymph node	7	6	9	22
20 T3NxM1	Primary lesion	6	3	7	4	0.019
Patients	Metastatic lymph node	4	3	4	9
	Distal metastatic site	3	5	2	10

Table 4 nm23-H1 immunoreactivity in primary and metastatic T3 gastric cancer

Patients (n)	Tumor type	Grade				P value
		-	+	++	+++
44 T3NxMx	Primary lesion	12	15	15	2	0.138
	Metastatic lymph node	22	9	7	6
20 T3NxM1	Primary lesion	8	4	7	1	0.497
	Metastatic lymph node	9	3	5	3
	Distal metastatic site	10	3	5	2